JP2024533234A5 - - Google Patents

Info

Publication number
JP2024533234A5
JP2024533234A5 JP2024514484A JP2024514484A JP2024533234A5 JP 2024533234 A5 JP2024533234 A5 JP 2024533234A5 JP 2024514484 A JP2024514484 A JP 2024514484A JP 2024514484 A JP2024514484 A JP 2024514484A JP 2024533234 A5 JP2024533234 A5 JP 2024533234A5
Authority
JP
Japan
Prior art keywords
antibody
seq
nucleic acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/074696 external-priority patent/WO2023031473A1/en
Publication of JP2024533234A publication Critical patent/JP2024533234A/ja
Publication of JP2024533234A5 publication Critical patent/JP2024533234A5/ja
Pending legal-status Critical Current

Links

JP2024514484A 2021-09-06 2022-09-06 Cd27に結合する能力を有する抗体、そのバリアントおよびその使用 Pending JP2024533234A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21195118 2021-09-06
EP21195118.1 2021-09-06
EP22173126 2022-05-12
EP22173126.8 2022-05-12
PCT/EP2022/074696 WO2023031473A1 (en) 2021-09-06 2022-09-06 Antibodies capable of binding to cd27, variants thereof and uses thereof

Publications (2)

Publication Number Publication Date
JP2024533234A JP2024533234A (ja) 2024-09-12
JP2024533234A5 true JP2024533234A5 (enExample) 2025-08-28

Family

ID=83400576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514484A Pending JP2024533234A (ja) 2021-09-06 2022-09-06 Cd27に結合する能力を有する抗体、そのバリアントおよびその使用

Country Status (14)

Country Link
US (4) US20230109496A1 (enExample)
EP (1) EP4399227A1 (enExample)
JP (1) JP2024533234A (enExample)
KR (1) KR20240051280A (enExample)
AR (1) AR127743A1 (enExample)
AU (1) AU2022338208A1 (enExample)
CA (1) CA3231003A1 (enExample)
CL (1) CL2024000669A1 (enExample)
CO (1) CO2024003578A2 (enExample)
IL (1) IL311141A (enExample)
MX (1) MX2024002781A (enExample)
PE (1) PE20240883A1 (enExample)
TW (1) TW202328192A (enExample)
WO (1) WO2023031473A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522657A1 (en) * 2022-05-12 2025-03-19 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ox40結合之抗體、其變異體及其用途
TW202540189A (zh) * 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ox40之抗體

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
BR112015022855A2 (pt) 2013-03-14 2017-11-07 Shire Human Genetic Therapies composições e método para produção de um anticorpo in vitro
EP3388834B1 (en) 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN109563511A (zh) 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US20190276549A1 (en) * 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗体のインビトロ糖鎖工学における酵素の再使用
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CN117887794A (zh) 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작
EP3580233A1 (en) 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
MA51666A (fr) 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations
EP3774903A1 (en) 2018-04-04 2021-02-17 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
JP2022546577A (ja) * 2019-09-05 2022-11-04 ソレント・セラピューティクス・インコーポレイテッド Bcmaと結合する二量体抗原受容体(dar)

Similar Documents

Publication Publication Date Title
CA2987118C (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
JP6526189B2 (ja) 抗pd−l1抗体並びにその治療及び診断のための使用
CA2932966C (en) Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2018126157A (ja) 抗cd40抗体および使用方法
JP2024533234A5 (enExample)
JP2020073499A (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
JP2016529882A5 (enExample)
JP2008291028A (ja) B細胞リンパ腫および細胞株の処置に効果的な二重特異性抗体
JP2022521723A (ja) クローディン6抗体及びその使用
CN115894701A (zh) 结合cd3的抗体及其用途
CN115461370B (zh) St2抗原结合蛋白
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
RU2770620C1 (ru) Связывающие молекулы, вызывающие клеточную активацию
JP2024054284A (ja) ガンの処置のための結合分子
TW201235358A (en) Antigen binding proteins
JP2024531900A (ja) 新規の抗sirpa抗体
JP2026508244A (ja) 抗Nectin-4抗体及びそれを含む多重特異性抗体
TW202144398A (zh) Cd137結合分子及其用途
JP2022520632A (ja) 共通軽鎖を含む抗体及びその使用
CN111303283A (zh) 抗il-17a抗体及其应用
RU2816204C2 (ru) Антитело против il-17a и его применение
WO2025126102A1 (en) Enpp3 × cd3 bispecific antibodies and use thereof
TW202602939A (zh) 一種多特異性抗體t細胞銜接器